13F History
Schedule 13D/G History
Ownership
Other Reports

COMMODORE CAPITAL LP - Significant Ownership

Signature - Title: Michael Kramarz - Managing Partner
Location: New York, NY
Summary: This page shows a list of all the recent SCHEDULE 13D/G filings made by COMMODORE CAPITAL LP.

Significant Ownership of COMMODORE CAPITAL LP

Sym	Company	Class	Ownership	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
CRDF	Cardiff Oncology, Inc.	Common Stock, $0.0001 par value	8.1%	$21.3M		5.38M		COMMODORE CAPITAL LP	Dec 10, 2024
SLDB	Solid Biosciences Inc.	Common Stock $0.001 par value per share	7.6%	$32.7M		5.83M		COMMODORE CAPITAL LP	Feb 18, 2025
DRUG	Bright Minds Biosciences Inc.	Common Shares, without par value	7.2%	$18M		500K		COMMODORE CAPITAL LP	Dec 31, 2024
MRUS	Merus N.V.	Common shares, (euro) 0.09 nominal value per share	5.5%	$178M		3.75M		Commodore Capital LP	Dec 9, 2024
VRDN	Viridian Therapeutics, Inc.	Common Stock, $0.01 par value per share	5.3%	$69.2M		4.3M		Commodore Capital LP	Apr 4, 2025
NRIX	Nurix Therapeutics, Inc.	Common Stock, par value $0.001 per share	5.1%	$50.8M		3.85M		COMMODORE CAPITAL LP	Feb 7, 2025
CLDX	Celldex Therapeutics, Inc.	Common Stock, par value $.001	5%	$70.9M		3.35M		COMMODORE CAPITAL LP	Apr 3, 2025
CELC	Celcuity Inc.	Common Stock, $0.001 par value per share	2.9%	$11M		1.1M		COMMODORE CAPITAL LP	Dec 31, 2024
NKTX	Nkarta, Inc.	Common Stock, $0.0001 par value per share	0.5%	$633K		352K		COMMODORE CAPITAL LP	Dec 31, 2024

Showing 1 to 9 of 9 entries

Schedules 13D/G Reported by COMMODORE CAPITAL LP:

Showing 0 to 0 of 0 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.